Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis

Bruce E. Sands; Laurent Peyrin-Biroulet; Edward V. Loftus; Silvio Danese; Jean-Frederic Colombel; Murat Toruner; Laimas Jonaitis; Brihad Abhyankar; Jingjing Chen; Raquel Rogers; Richard A. Lirio; Jeffrey D. Bornstein; Stefan Schreiber; Marieke Pierik; VARSITY Study Group

doi:10.1056/NEJMoa1905725

Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis

Bruce E. Sands, Laurent Peyrin-Biroulet, Edward V. Loftus, Silvio Danese, Jean-Frederic Colombel, Murat Toruner, Laimas Jonaitis, Brihad Abhyankar, Jingjing Chen, Raquel Rogers, Richard A. Lirio, Jeffrey D. Bornstein, Stefan Schreiber, Marieke Pierik, VARSITY Study Group

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	1215-1226
Number of pages	12
Journal	New England Journal of Medicine
Volume	381
Issue number	13
DOIs	https://doi.org/10.1056/NEJMoa1905725
Publication status	Published - 26 Sep 2019

Keywords

EFFICACY
THERAPY
DISEASE
SCORE

Access to Document

10.1056/NEJMoa1905725

Cite this

Sands, B. E., Peyrin-Biroulet, L., Loftus, E. V., Danese, S., Colombel, J-F., Toruner, M., Jonaitis, L., Abhyankar, B., Chen, J., Rogers, R., Lirio, R. A., Bornstein, J. D., Schreiber, S., Pierik, M., & VARSITY Study Group (2019). Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. New England Journal of Medicine, 381(13), 1215-1226. https://doi.org/10.1056/NEJMoa1905725

Sands, Bruce E. ; Peyrin-Biroulet, Laurent ; Loftus, Edward V. ; Danese, Silvio ; Colombel, Jean-Frederic ; Toruner, Murat ; Jonaitis, Laimas ; Abhyankar, Brihad ; Chen, Jingjing ; Rogers, Raquel ; Lirio, Richard A. ; Bornstein, Jeffrey D. ; Schreiber, Stefan ; Pierik, Marieke ; VARSITY Study Group. / Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. In: New England Journal of Medicine. 2019 ; Vol. 381, No. 13. pp. 1215-1226.

@article{4166528de7984334bcc5779297c88ad9,

title = "Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis",

keywords = "EFFICACY, THERAPY, DISEASE, SCORE",

author = "Sands, {Bruce E.} and Laurent Peyrin-Biroulet and Loftus, {Edward V.} and Silvio Danese and Jean-Frederic Colombel and Murat Toruner and Laimas Jonaitis and Brihad Abhyankar and Jingjing Chen and Raquel Rogers and Lirio, {Richard A.} and Bornstein, {Jeffrey D.} and Stefan Schreiber and Marieke Pierik and {VARSITY Study Group}",

year = "2019",

month = sep,

day = "26",

doi = "10.1056/NEJMoa1905725",

language = "English",

volume = "381",

pages = "1215--1226",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "MASSACHUSETTS MEDICAL SOCIETY",

number = "13",

}

Sands, BE, Peyrin-Biroulet, L, Loftus, EV, Danese, S, Colombel, J-F, Toruner, M, Jonaitis, L, Abhyankar, B, Chen, J, Rogers, R, Lirio, RA, Bornstein, JD, Schreiber, S, Pierik, M & VARSITY Study Group 2019, 'Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis', New England Journal of Medicine, vol. 381, no. 13, pp. 1215-1226. https://doi.org/10.1056/NEJMoa1905725

Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. / Sands, Bruce E.; Peyrin-Biroulet, Laurent; Loftus, Edward V.; Danese, Silvio; Colombel, Jean-Frederic; Toruner, Murat; Jonaitis, Laimas; Abhyankar, Brihad; Chen, Jingjing; Rogers, Raquel; Lirio, Richard A.; Bornstein, Jeffrey D.; Schreiber, Stefan; Pierik, Marieke; VARSITY Study Group.

In: New England Journal of Medicine, Vol. 381, No. 13, 26.09.2019, p. 1215-1226.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis

AU - Sands, Bruce E.

AU - Peyrin-Biroulet, Laurent

AU - Loftus, Edward V.

AU - Danese, Silvio

AU - Colombel, Jean-Frederic

AU - Toruner, Murat

AU - Jonaitis, Laimas

AU - Abhyankar, Brihad

AU - Chen, Jingjing

AU - Rogers, Raquel

AU - Lirio, Richard A.

AU - Bornstein, Jeffrey D.

AU - Schreiber, Stefan

AU - Pierik, Marieke

AU - VARSITY Study Group

PY - 2019/9/26

Y1 - 2019/9/26

KW - EFFICACY

KW - THERAPY

KW - DISEASE

KW - SCORE

U2 - 10.1056/NEJMoa1905725

DO - 10.1056/NEJMoa1905725

M3 - Article

VL - 381

SP - 1215

EP - 1226

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 13

ER -